Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.

Dermatologic therapy - 1 May 2020

Patruno Cataldo, Stingeni Luca, Hansel Katharina, Ferrucci Silvia Mariel, Tavecchio Simona, Fabbrocini Gabriella, Nisticò Steven Paul, Foti Caterina, De Prezzo Serena, Napolitano Maddalena

Abstract excerpt

Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dermatitis, Atopic

Share to Eczema

Share to Phenotype

Share to Severity of Illness Index

Source

Identifiers

PMID: 32125741
DOI: 10.1111/dth.13290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.PMID 32125741Read ↗

Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 PatientsSemantic proximity Read ↗

Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis.Semantic proximity Read ↗

Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.Semantic proximity Read ↗

Clinical phenotypes of adult atopic dermatitis and related therapies.Semantic proximity Read ↗

Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.Semantic proximity Read ↗

Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report.Semantic proximity Read ↗

Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.Semantic proximity Read ↗

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.Semantic proximity Read ↗

Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling.Semantic proximity Read ↗

Generalized eczematous dermatitis and pruritus responsive to dupilumab in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.Semantic proximity Read ↗

Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review.Semantic proximity Read ↗

Complementary Use of a Next-Generation Emollient Plus and Pimecrolimus in Atopic Dermatitis: A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.